Tags

Type your tag names separated by a space and hit enter

[Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development].
Pol Arch Med Wewn 2007; 117 Suppl:13-7PA

Abstract

INTRODUCTION

Atherosclerosis is an important clinical problem in patients with systemic lupus erythematosus (SLE), because of very severe cardiovascular and central nervous system manifestations.

OBJECTIVES

Estimation if antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) are risk factors for subclinical atherosclerosis in patients with SLE.

PATIENTS AND METHODS

We examined 103 patients with SLE and 30 healthy volunteers, included as the control group. Coexistence of APS was confirmed in 35 patients. Evaluation of subclinical atherosclerosis was done on the basis of measurement of intima-media thickness (IMT) in B-mode ultrasound examination. We considered classical atherosclerotic risk factors and determined profile of aPL: anti-cardiolipine antibodies (aCL), anti beta2 glycoprotein-I antibodies, antiprothrombin antibodies (aPT), anti-oxidized low-density lipoprotein antibodies and lupus anticoagulant (LA). Statistical analysis was performed with chi2 Yates, chi2 Pearson and R rang Spearman tests. Multivariate regression analysis was also done.

RESULTS

Thickened IMT was significantly more frequent in patients with SLE than in controls (p = 0.0002). We found that coexistence of APS is a risk factor for moderate thickening of IMT (OR: 3.41; 95% CI: 1.0-11.5). We also confirmed that the presence of aPL is significantly correlated with IMT ranging from 0.66 to 0.86 mm. The highest risk was found in patients with the presence of aPT IgA (OR: 5.50; 95% CI: 1.1-30.2), aCL IgM (OR: 4.36; 95% CI: 1.1-20.7), LA (OR: 4.02; 95% CI: 1.1-19.4) and aCL IgG (OR: 2.99; 95% CI: 1.1-9.7). Moreover, we found that ischaemic heart disease, nephropathy and myocardial infarction were significantly more frequent in patients with thickened IMT.

CONCLUSIONS

Patients with SLE develop subclinical atherosclerosis significantly more frequent than the general population. Coexistence of APS and presence of aPL are risk factors for subclinical atherosclerosis development in patients with SLE. Thickened intima-media in patients with SLE is significantly associated with an increased risk of cardiovascular manifestations.

Authors+Show Affiliations

Klinika Reumatologii, Pomorska Akademia Medyczna, Szczecin. labreum@sci.pam.szczecin.plNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

pol

PubMed ID

18778013

Citation

Fischer, Katarzyna, et al. "[Significance of Antiphospholipid Syndrome and Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus in Estimation of Risk of Subclinical Atherosclerosis Development]." Polskie Archiwum Medycyny Wewnetrznej, vol. 117 Suppl, 2007, pp. 13-7.
Fischer K, Brzosko M, Walecka A, et al. [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development]. Pol Arch Med Wewn. 2007;117 Suppl:13-7.
Fischer, K., Brzosko, M., Walecka, A., Ostanek, L., & Sawicki, M. (2007). [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development]. Polskie Archiwum Medycyny Wewnetrznej, 117 Suppl, pp. 13-7.
Fischer K, et al. [Significance of Antiphospholipid Syndrome and Antiphospholipid Antibodies in Patients With Systemic Lupus Erythematosus in Estimation of Risk of Subclinical Atherosclerosis Development]. Pol Arch Med Wewn. 2007;117 Suppl:13-7. PubMed PMID: 18778013.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development]. AU - Fischer,Katarzyna, AU - Brzosko,Marek, AU - Walecka,Anna, AU - Ostanek,Lidia, AU - Sawicki,Marcin, PY - 2008/9/10/pubmed PY - 2008/10/4/medline PY - 2008/9/10/entrez SP - 13 EP - 7 JF - Polskie Archiwum Medycyny Wewnetrznej JO - Pol. Arch. Med. Wewn. VL - 117 Suppl N2 - INTRODUCTION: Atherosclerosis is an important clinical problem in patients with systemic lupus erythematosus (SLE), because of very severe cardiovascular and central nervous system manifestations. OBJECTIVES: Estimation if antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) are risk factors for subclinical atherosclerosis in patients with SLE. PATIENTS AND METHODS: We examined 103 patients with SLE and 30 healthy volunteers, included as the control group. Coexistence of APS was confirmed in 35 patients. Evaluation of subclinical atherosclerosis was done on the basis of measurement of intima-media thickness (IMT) in B-mode ultrasound examination. We considered classical atherosclerotic risk factors and determined profile of aPL: anti-cardiolipine antibodies (aCL), anti beta2 glycoprotein-I antibodies, antiprothrombin antibodies (aPT), anti-oxidized low-density lipoprotein antibodies and lupus anticoagulant (LA). Statistical analysis was performed with chi2 Yates, chi2 Pearson and R rang Spearman tests. Multivariate regression analysis was also done. RESULTS: Thickened IMT was significantly more frequent in patients with SLE than in controls (p = 0.0002). We found that coexistence of APS is a risk factor for moderate thickening of IMT (OR: 3.41; 95% CI: 1.0-11.5). We also confirmed that the presence of aPL is significantly correlated with IMT ranging from 0.66 to 0.86 mm. The highest risk was found in patients with the presence of aPT IgA (OR: 5.50; 95% CI: 1.1-30.2), aCL IgM (OR: 4.36; 95% CI: 1.1-20.7), LA (OR: 4.02; 95% CI: 1.1-19.4) and aCL IgG (OR: 2.99; 95% CI: 1.1-9.7). Moreover, we found that ischaemic heart disease, nephropathy and myocardial infarction were significantly more frequent in patients with thickened IMT. CONCLUSIONS: Patients with SLE develop subclinical atherosclerosis significantly more frequent than the general population. Coexistence of APS and presence of aPL are risk factors for subclinical atherosclerosis development in patients with SLE. Thickened intima-media in patients with SLE is significantly associated with an increased risk of cardiovascular manifestations. UR - https://www.unboundmedicine.com/medline/citation/18778013/[Significance_of_antiphospholipid_syndrome_and_antiphospholipid_antibodies_in_patients_with_systemic_lupus_erythematosus_in_estimation_of_risk_of_subclinical_atherosclerosis_development]_ L2 - http://pamw.pl/en/issue/article/18778013 DB - PRIME DP - Unbound Medicine ER -